An audit of relapsed ovarian cancer (OC) management in 9 UK centres

5138 Background: Relapsed ovarian cancer has a poor prognosis but in recent years treatment has improved as new agents have been licensed. As the range of available agents becomes wider, the need increases to audit the outcomes achieved with each regimen in real clinical practice. Such audit is increasingly a requirement of UK national guidance on the appropriate use of these agents. However, it is difficult to obtain meaningful results in many centres, when the range of potential regimens is wide, and the number of patients treated for relapsed OC relatively small.Thus it was the aim of this audit to describe the patterns of chemotherapy usage and associated outcomes in patients with relapsed OC, pooling the data from 9 UK centres to provide robust results which could inform future management of the disease. Methods: Ovarian cancer patients in 9 UK hospitals who received treatment for recurrent disease between Aug 2001 and Feb 2004 were included in the analysis using a common data set. End points include...